Literature DB >> 12367706

HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies.

Dennis Kitzman1, Kuei-Ju Cheng, Lawrence Fleckenstein.   

Abstract

A sensitive and selective HPLC chromatography method using UV detection (295 nm) was developed for the determination of albendazole, albendazole sulfoxide (ABZSO), and albendazole sulfone (ABZSO2) in human plasma. Albendazole, ABZSO, ABZSO2, and the internal standard, oxibendazole, were extracted from human plasma by loading onto a conditioned C(18) SPE cartridge, rinsing with 15% methanol, and eluting with 90% methanol. Samples were evaporated under a stream of nitrogen, reconstituted with mobile phase, 1.25% triethylamine in water-methanol-acetonitrile (72:15:13, v/v/v) (pH* 3.1), and injected onto a Waters muBondapak Phenyl 3.9 x 300 mm HPLC column. Mobile phase flow rate was 1.0 ml/min. The retention times of albendazole, ABZSO, ABZSO2, and the internal standard were approximately 24.4, 7.9, 13.4, and 11.3 min, respectively. Total run time was 30 min. The assay was linear for concentration ranges in human plasma of 20-600 ng/ml for albendazole, 20-1000 ng/ml for ABZSO, and 20-300 ng/ml for ABZSO2. The analysis of quality control samples demonstrated excellent precision. Coefficients of variation for albendazole (20, 400, 600 ng/ml) were 6.7, 8.1 and 7.0%; ABZSO (20, 400, 800 ng/ml) were 6.0, 8.5 and 5.9%; ABZSO2 (20, 150, 300 ng/ml) were 3.1, 3.9 and 2.3%, respectively. The method appears to be robust and has been applied to a pharmacokinetic study of albendazole in healthy volunteers. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12367706     DOI: 10.1016/s0731-7085(02)00382-5

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Preparative microfluidic electrosynthesis of drug metabolites.

Authors:  Romain Stalder; Gregory P Roth
Journal:  ACS Med Chem Lett       Date:  2013-10-01       Impact factor: 4.345

2.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

3.  Use of albendazole sulfoxide, albendazole sulfone, and combined solutions as scolicidal agents on hydatid cysts (in vitro study).

Authors:  Gokhan Adas; Soykan Arikan; Ozgur Kemik; Ali Oner; Nilgun Sahip; Oguzhan Karatepe
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

4.  Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers.

Authors:  I M Rigter; H G Schipper; R P Koopmans; H J M van Kan; H W Frijlink; P A Kager; H-J Guchelaar
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Determination of albendazole and metabolites in silkworm Bombyx mori hemolymph by ultrafast liquid chromatography tandem triple quadrupole mass spectrometry.

Authors:  Li Li; Dong-Xu Xing; Qing-Rong Li; Yang Xiao; Ming-Qiang Ye; Qiong Yang
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

6.  Liquid chromatography--tandem mass spectrometry method for simultaneous determination of albendazole and albendazole sulfoxide in human plasma for bioequivalence studies.

Authors:  Dhiraj M Rathod; Keyur R Patel; Hiren N Mistri; Arvind G Jangid; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2016-02-24

7.  Exploring the Preparation of Albendazole-Loaded Chitosan-Tripolyphosphate Nanoparticles.

Authors:  Bong-Seok Kang; Sang-Eun Lee; Choon Lian Ng; Jin-Ki Kim; Jeong-Sook Park
Journal:  Materials (Basel)       Date:  2015-02-05       Impact factor: 3.623

8.  Quantitative Analysis of Abamectin, Albendazole, Levamisole HCl and Closantel in Q-DRENCH Oral Suspension Using a Stability-Indicating HPLC-DAD Method.

Authors:  Hazim M Ali; Mohammed Gamal; Mohammed M Ghoneim; Lobna Mohammed Abd Elhalim
Journal:  Molecules       Date:  2022-01-24       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.